The National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns.
The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.
Detailed information on this clinical alert can be found at: http://www.nlm.nih.gov/databases/alerts/2011_nhlbi_ifp.html
No comments:
Post a Comment